Multivariate analysis on NRM and interactions between conditioning intensity and each covariate in the training cohort
| . | HR (95% CI) . | P values . | Interaction P values . |
|---|---|---|---|
| Conditioning intensity | |||
| Myeloablative | 1 | Reference | |
| Reduced intensity | 0.90 (0.79-1.01) | .080 | |
| Age, category | |||
| <60 | 1 | Reference | .200 |
| ≥60 | 1.21 (1.07-1.37) | .003 | |
| Sex match between recipient and donor | |||
| Female recipient or male to male | 1 | Reference | .300 |
| Female to male | 1.19 (1.04-1.36) | .014 | |
| Disease | |||
| AML | 1 | Reference | |
| ALL | 1.18 (1.00-1.39) | .049 | .580 |
| MDS | 1.23 (1.07-1.43) | .004 | .420 |
| DRI | |||
| Low or intermediate risk | 1 | Reference | .240 |
| High risk | 0.89 (0.76-1.04) | .140 | |
| KPS | |||
| >80% | 1 | Reference | .240 |
| ≤80% | 1.36 (1.16-1.58) | <.001 | |
| HCT-CI | |||
| <2 | 1 | Reference | .077 |
| ≥2 | 1.16 (1.02-1.31) | .021 | |
| Donor type | |||
| HLA-MRD | 1 | Reference | |
| HLA-MUD | 1.27 (1.03-1.56) | .025 | .640 |
| HLA-MMUD | 1.67 (1.34-2.08) | <.001 | .660 |
| UCB | 1.41 (1.16-1.72) | <.001 | .087 |
| Donor source∗ | |||
| Bone marrow | 1 | Reference | |
| Peripheral blood | 1.08 (0.87-1.35) | .500 | .700 |
| GVHD prophylaxis | |||
| CSA-based | 1 | Reference | .490 |
| TAC-based | 0.87 (0.74-1.02) | .089 | |
| In vivo T-cell depletion | |||
| No | 1 | Reference | .250 |
| Yes | 0.76 (0.60-0.97) | .027 | |
| Median y of HCT, (range) | 0.98 (0.96-0.99) | .010 | |
| . | HR (95% CI) . | P values . | Interaction P values . |
|---|---|---|---|
| Conditioning intensity | |||
| Myeloablative | 1 | Reference | |
| Reduced intensity | 0.90 (0.79-1.01) | .080 | |
| Age, category | |||
| <60 | 1 | Reference | .200 |
| ≥60 | 1.21 (1.07-1.37) | .003 | |
| Sex match between recipient and donor | |||
| Female recipient or male to male | 1 | Reference | .300 |
| Female to male | 1.19 (1.04-1.36) | .014 | |
| Disease | |||
| AML | 1 | Reference | |
| ALL | 1.18 (1.00-1.39) | .049 | .580 |
| MDS | 1.23 (1.07-1.43) | .004 | .420 |
| DRI | |||
| Low or intermediate risk | 1 | Reference | .240 |
| High risk | 0.89 (0.76-1.04) | .140 | |
| KPS | |||
| >80% | 1 | Reference | .240 |
| ≤80% | 1.36 (1.16-1.58) | <.001 | |
| HCT-CI | |||
| <2 | 1 | Reference | .077 |
| ≥2 | 1.16 (1.02-1.31) | .021 | |
| Donor type | |||
| HLA-MRD | 1 | Reference | |
| HLA-MUD | 1.27 (1.03-1.56) | .025 | .640 |
| HLA-MMUD | 1.67 (1.34-2.08) | <.001 | .660 |
| UCB | 1.41 (1.16-1.72) | <.001 | .087 |
| Donor source∗ | |||
| Bone marrow | 1 | Reference | |
| Peripheral blood | 1.08 (0.87-1.35) | .500 | .700 |
| GVHD prophylaxis | |||
| CSA-based | 1 | Reference | .490 |
| TAC-based | 0.87 (0.74-1.02) | .089 | |
| In vivo T-cell depletion | |||
| No | 1 | Reference | .250 |
| Yes | 0.76 (0.60-0.97) | .027 | |
| Median y of HCT, (range) | 0.98 (0.96-0.99) | .010 | |
CSA, cyclosporine; TAC, tacrolimus.
Donor source was included in different multivariate model that exclude UCB.